Comparative Pharmacology
Head-to-head clinical analysis: NALOXONE HCL versus ZIMHI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NALOXONE HCL versus ZIMHI.
NALOXONE HCL vs ZIMHI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist at mu, kappa, and delta opioid receptors, reversing opioid-induced respiratory depression and analgesia.
Opioid receptor antagonist; reverses opioid effects by competitively binding to mu-opioid receptors.
0.4 mg to 2 mg IV, IM, or subcutaneously, may repeat every 2-3 minutes as needed. For continuous infusion, IV infusion rate of 0.25-6.25 mg/hour.
5 mg intramuscularly every 2-3 minutes as needed; maximum 3 doses.
None Documented
None Documented
Terminal elimination half-life is 1.0-1.5 hours in adults. In neonates, half-life is prolonged (3-4 hours) due to immature hepatic function. Clinically, the short half-life necessitates repeated or continuous dosing to reverse opioid effects lasting longer than naloxone's duration.
Terminal half-life: 2.5-4 hours; clinical context: short duration requires repeat dosing for sustained opioid effects.
Primarily hepatic metabolism (glucuronidation). Renal excretion accounts for approximately 50% of total clearance, with biliary/fecal elimination contributing 20-30%. Unchanged naloxone in urine is <5%.
Renal: 30-35% unchanged; biliary/fecal: 50-60% as metabolites.
Category A/B
Category C
Opioid Antagonist
Opioid Antagonist